SCI (4119) reported revenue of NT$131 million for Oct 2026, +30.4% year on year and -19.8% from the previous month. Revenue for Jan–Oct 2026 was NT$1.28 billion (+17.8% year on year).
Year-on-year revenue growth: 5 months in a row. →
In Oct 2026, it ranked No. 63 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$131 million | +30.4% | -19.8% |
| Sep 2026 | NT$163.4 million | +33.1% | +9.7% |
| Aug 2026 | NT$149 million | +187.5% | -21.9% |
| Jul 2026 | NT$190.8 million | +133.2% | +54.8% |
| Jun 2026 | NT$123.2 million | +36.1% | +102.3% |
| May 2026 | NT$60.9 million | -47.1% | -31.3% |
| Apr 2026 | NT$88.7 million | -46.5% | -30.5% |
| Mar 2026 | NT$127.6 million | -24.4% | +7.7% |
| Feb 2026 | NT$118.5 million | +39.9% | -8.6% |
| Jan 2026 | NT$129.7 million | +21.4% | -14.5% |
| Dec 2025 | NT$151.6 million | +94.5% | +46.7% |
| Nov 2025 | NT$103.4 million | -33.5% | +2.9% |
| Oct 2025 | NT$100.5 million | -40.3% | -18.2% |
| Sep 2025 | NT$122.8 million | -7.2% | +137.0% |
| Aug 2025 | NT$51.8 million | -65.6% | -36.7% |
| Jul 2025 | NT$81.8 million | -40.1% | -9.6% |
| Jun 2025 | NT$90.5 million | -21.5% | -21.4% |
| May 2025 | NT$115.2 million | -0.1% | -30.5% |
| Apr 2025 | NT$165.8 million | +2.2% | -1.8% |
| Mar 2025 | NT$168.8 million | +18.0% | +99.3% |
| Feb 2025 | NT$84.7 million | +14.4% | -20.7% |
| Jan 2025 | NT$106.9 million | +15.0% | +37.1% |
| Dec 2024 | NT$78 million | -12.2% | -49.9% |
| Nov 2024 | NT$155.5 million | +43.2% | -7.6% |
| Oct 2024 | NT$168.4 million | +78.9% | +27.2% |
Jan–Oct 2026 cumulative: NT$1.28 billion (+17.8% YoY)
Other Biotech & Medical companies
Compare with peers: SCI vs PEC / SCI vs Lotus Pharm / SCI vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16